<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011335</url>
  </required_header>
  <id_info>
    <org_study_id>IDCRP-035/Nabi-6801</org_study_id>
    <secondary_id>Nabi-W81XWH-09-2-0151</secondary_id>
    <secondary_id>USAMRAA Grant #DR081318P1</secondary_id>
    <nct_id>NCT01011335</nct_id>
  </id_info>
  <brief_title>Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial</brief_title>
  <official_title>A Randomized, Multi-Center Trial to Evaluate the Safety &amp; Immunogenicity of Staphylococcus Aureus Toxoids, rAT and rLukS-PV, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Uniformed Services University of the Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves the use of investigational vaccines. A vaccine is a medicine that causes
      the body to make antibodies. Antibodies help destroy foreign substances that enter the body.
      The purpose of this study is to find the right dose of a new vaccine that is safe and
      produces a good immune response (how well your body recognizes and defends itself against
      harmful foreign substances). There are two Staphylococcus aureus toxoids (components or
      antigens) under investigation in this study; one of them is a protein known as rAT and the
      other is a protein known as rLukS-PV. They are being developed to see if they are effective
      at preventing infections caused by the bacteria Staphylococcus aureus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Staphylococcus aureus is a leading cause of skin and soft tissue infections. Antibiotic
      resistance, such as seen with new community-acquired methicillin-resistant strains, presents
      a major challenge in treating and preventing these infections. Therefore, a preventative
      vaccine is considered a potentially better approach.

      This study assesses the safety and immunogenicity of monovalent and bivalent S. aureus
      vaccine components. Healthy adult subjects will be randomized to receive 1 dose of monovalent
      or bivalent toxoid vaccine, or placebo in a dose escalation schedule.

      Antigen-specific antibody will be measured by ELISA in sera collected for three months after
      injection. Safety data will be collected as 7 day reactogenicity diaries after each
      injection, adverse events and Staphylococcus aureus and skin and soft tissue infections will
      be collected through Day 84, and serious adverse events and chronic illnesses will be
      collected for the full 6 month study period.

      To evaluate the possible utility of booster doses, the cohort receiving the highest dose of
      bivalent antigen will have a 2nd dose administered at Day 84, with a new 7-day reactogenicity
      diary and sera collected after the 2nd dose. All subjects will be followed up with a 6 month
      phone call after vaccination or booster.

      The total subject observation period will be for 24 weeks from Day 0, plus 12 additional
      weeks for the cohorts that receive a 2nd dose. With a recruitment period of 4 months, the
      study duration is expected to be approximately 13 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Adverse events, local reactogenicity, and systemic reactogenicity were assessed through clinical examination by study providers, clinical lab results, as well as review of subject-completed diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity: Geometric Mean Concentrations After First Injection, Completer Population</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. Immunogenicity was determined on the basis of anti-rAT and anti-rLukS-PV IgG concentrations assessed by enzyme-linked immunosorbent assay (ELISA) in sera from blood samples collected on Days 0 (baseline), 14, 28 and 84 for those receiving a single dose of vaccine. For those receiving a second dose of vaccine, immunogenicity assessments were also conducted on Days 98 and 112. Immunogenicity was evaluated using the following metrics: geometric mean concentrations (GMCs), geometric mean fold increase (GMFIs) and seroresponse status. Seroresponse variables are normally defined in terms of exceeding a threshold.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>Active Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with Alum</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent rAT</intervention_name>
    <description>10, 25, 50 or 100 μg</description>
    <arm_group_label>Active Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent rLukS-PV</intervention_name>
    <description>10, 25, 50 or 100 μg</description>
    <arm_group_label>Active Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bivalent rLukS-PV / rAT</intervention_name>
    <description>10, 25 or 50 μg</description>
    <arm_group_label>Active Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo with adjuvant</intervention_name>
    <description>Placebo with adjuvant</description>
    <arm_group_label>Placebo with Alum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo saline</description>
    <arm_group_label>Saline Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males or females, DoD beneficiaries, including active duty members,
             18-55 years of age.

          -  Negative urine pregnancy test for female subjects of child bearing potential (negative
             test within 24 hours prior to investigational product injection) or documented
             surgical sterility.

          -  Female subjects of child-bearing potential must use an acceptable method of birth
             control, as determined by the PI.

          -  Willingness to participate in this study as evidenced by written informed consent.

        Exclusion Criteria:

          -  Prior receipt of S. aureus rAT or rLukS-PV

          -  Known S. aureus infection requiring medical treatment within the 3 months prior to
             investigational drug product injection

          -  Known active viral or bacterial infection

          -  Seropositivity for HIV infection

          -  Known or suspected abuse of prescribed or illicit drugs, or alcohol in the past year

          -  Use of any new medications (except oral contraceptives, over-the-counter medications,
             or vitamin supplements) within the 7 days prior to investigational drug product
             injection

          -  Use of investigational drugs, vaccines, or devices during the study or within the 30
             days prior to each dose of investigational drug product injection, or anticipated use
             of such items during the study

          -  Use of systemic steroids (any dose) or high daily dose inhaled steroids within the
             last month. Use of low or medium daily dose inhaled, intranasal, or low potency
             topical steroid creams/ointments is allowed unless such medication was begun within
             the previous 7 days.

          -  History of a bleeding or coagulation disorder; or use of anti-coagulant medications
             within 7 days prior to investigational product injection

          -  Actively breastfeeding

          -  Presence of grade I or higher abnormality in laboratory or vital signs parameter at
             time of screening

          -  Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L Landrum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Kessler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>June 21, 2013</results_first_submitted>
  <results_first_submitted_qc>December 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uniformed Services University of the Health Sciences</investigator_affiliation>
    <investigator_full_name>David Tribble</investigator_full_name>
    <investigator_title>Director, General Infectious Diseases, Infectious Disease Clinical Research Program</investigator_title>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Skin and soft tissue infection</keyword>
  <keyword>Methicillin-resistant Staphylococcus aureus</keyword>
  <keyword>Recombinant alpha-toxoid (rAT)</keyword>
  <keyword>Recombinant LukS subunit of Panton-Valentine Leukocidin (rLukS-PV)</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible subjects were recruited from two clinical sites: San Antonio Military Medical Center, San Antonio, TX and Naval Medical Center, Portsmouth, VA between August 2010 and February 2011.</recruitment_details>
      <pre_assignment_details>Subjects who consented to the study but who were not randomized were those who either failed screening due to abnormal baseline laboratory results, or who met screening criteria but became ineligible to receive a study injection or were unavailable at the time of injection. Subjects who were unavailable at the time of injection were replaced.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Monovalent rAT 10 ug Dose</title>
          <description>Intramuscular; Monovalent rAT : 10 μg; single timepoint</description>
        </group>
        <group group_id="P2">
          <title>Monovalent rAT 25 ug Dose</title>
          <description>Intramuscular; Monovalent rAT : 25 μg; single timepoint</description>
        </group>
        <group group_id="P3">
          <title>Monovalent rAT 50 ug Dose</title>
          <description>Intramuscular; Monovalent rAT : 50 μg; single timepoint</description>
        </group>
        <group group_id="P4">
          <title>Monovalent rAT 100 ug Dose</title>
          <description>Intramuscular; Monovalent rAT : 100 μg; single timepoint</description>
        </group>
        <group group_id="P5">
          <title>Monovalent rLukS 10 ug Dose</title>
          <description>Intramuscular; Monovalent rLukS-PV : 10 μg; single timepoint</description>
        </group>
        <group group_id="P6">
          <title>Monovalent rLukS 25 ug Dose</title>
          <description>Intramuscular; Monovalent rLukS-PV : 25 μg; single timepoint</description>
        </group>
        <group group_id="P7">
          <title>Monovalent rLukS 50 ug Dose</title>
          <description>Intramuscular; Monovalent rLukS-PV : 50 μg; single timepoint</description>
        </group>
        <group group_id="P8">
          <title>Monovalent rLukS 100 ug Dose</title>
          <description>Intramuscular; Monovalent rLukS-PV : 100 μg; single timepoint</description>
        </group>
        <group group_id="P9">
          <title>Bivalent rAT/rLukS 10 ug Dose</title>
          <description>Intramuscular; Bivalent rAT/rLukS : 10 μg; single timepoint</description>
        </group>
        <group group_id="P10">
          <title>Bivalent rAT/rLukS 25 ug Dose</title>
          <description>Intramuscular; Bivalent rAT/rLukS : 25 μg; single timepoint</description>
        </group>
        <group group_id="P11">
          <title>Bivalent rAT/rLukS 50 ug Dose</title>
          <description>Intramuscular; Bivalent rAT/rLukS : 50 μg; single timepoint</description>
        </group>
        <group group_id="P12">
          <title>Alum Placebo</title>
          <description>Intramuscular; Alum placebo : 10, 25, 50, 100 μg; single timepoint</description>
        </group>
        <group group_id="P13">
          <title>Normal Saline Placebo</title>
          <description>Intramuscular; Saline Placebo : 10, 25, 50, 100 μg; single timepoint</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="12"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="22"/>
                <participants group_id="P13" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="21"/>
                <participants group_id="P13" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved/deployed or no booster</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Monovalent rAT Doses</title>
          <description>Monovalent rAT : 10, 25, 50 or 100 μg</description>
        </group>
        <group group_id="B2">
          <title>Monovalent rLukS-PV Doses</title>
          <description>Monovalent rLukS-PV : 10, 25, 50 or 100 μg</description>
        </group>
        <group group_id="B3">
          <title>Bivalent rAT/rLukS-PV Doses</title>
          <description>Bivalent rLukS-PV / rAT : 10, 25 or 50 μg</description>
        </group>
        <group group_id="B4">
          <title>Placebo Doses</title>
          <description>Saline placebo or alum placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="10.0"/>
                    <measurement group_id="B2" value="31.1" spread="8.6"/>
                    <measurement group_id="B3" value="32.0" spread="8.6"/>
                    <measurement group_id="B4" value="32.9" spread="10.2"/>
                    <measurement group_id="B5" value="32.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports</title>
        <description>Adverse events, local reactogenicity, and systemic reactogenicity were assessed through clinical examination by study providers, clinical lab results, as well as review of subject-completed diary</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monovalent rAT Doses</title>
            <description>Monovalent rAT 10µg, 25µg, 50µg, 100µg</description>
          </group>
          <group group_id="O2">
            <title>Monovalent rLukS Doses</title>
            <description>Monovalent rLukS 10µg, 25µg, 50µg, 100µg</description>
          </group>
          <group group_id="O3">
            <title>Bivalent rAT/rLukS Doses</title>
            <description>rAT/rLukS 10µg, 25µg, 50µg</description>
          </group>
          <group group_id="O4">
            <title>Placebo Doses</title>
            <description>Alum placebo and Saline placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports</title>
          <description>Adverse events, local reactogenicity, and systemic reactogenicity were assessed through clinical examination by study providers, clinical lab results, as well as review of subject-completed diary</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local or Systemic Reactogenicity Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity: Geometric Mean Concentrations After First Injection, Completer Population</title>
        <description>Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. Immunogenicity was determined on the basis of anti-rAT and anti-rLukS-PV IgG concentrations assessed by enzyme-linked immunosorbent assay (ELISA) in sera from blood samples collected on Days 0 (baseline), 14, 28 and 84 for those receiving a single dose of vaccine. For those receiving a second dose of vaccine, immunogenicity assessments were also conducted on Days 98 and 112. Immunogenicity was evaluated using the following metrics: geometric mean concentrations (GMCs), geometric mean fold increase (GMFIs) and seroresponse status. Seroresponse variables are normally defined in terms of exceeding a threshold.</description>
        <time_frame>Up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>rAT 10 µg</title>
          </group>
          <group group_id="O2">
            <title>rAT 25 µg</title>
          </group>
          <group group_id="O3">
            <title>rAT 50 µg</title>
          </group>
          <group group_id="O4">
            <title>rAT 100 µg</title>
          </group>
          <group group_id="O5">
            <title>rAT/rLukS 10 µg (for rAT)</title>
          </group>
          <group group_id="O6">
            <title>rAT/rLukS 25 µg (for rAT)</title>
          </group>
          <group group_id="O7">
            <title>rAT/rLukS 50 µg (for rAT)</title>
          </group>
          <group group_id="O8">
            <title>Alum Placebo (for rAT)</title>
          </group>
          <group group_id="O9">
            <title>Saline Placebo (for rAT)</title>
          </group>
          <group group_id="O10">
            <title>rLukS 10 µg</title>
          </group>
          <group group_id="O11">
            <title>rLukS 25 µg</title>
          </group>
          <group group_id="O12">
            <title>rLukS 50 µg</title>
          </group>
          <group group_id="O13">
            <title>rLukS 100 µg</title>
          </group>
          <group group_id="O14">
            <title>rAT/rLukS 10 µg (for rLukS)</title>
          </group>
          <group group_id="O15">
            <title>rAT/rLukS 25 µg (for rLukS)</title>
          </group>
          <group group_id="O16">
            <title>rAT/rLukS 50 µg (for rLukS)</title>
          </group>
          <group group_id="O17">
            <title>Alum Placebo (for rLukS)</title>
          </group>
          <group group_id="O18">
            <title>Normal Saline Placebo (for rLukS)</title>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Geometric Mean Concentrations After First Injection, Completer Population</title>
          <description>Immunogenicity is the ability of a particular substance, such as an antigen or epitope, to provoke an immune response in the body of a human or animal. Immunogenicity was determined on the basis of anti-rAT and anti-rLukS-PV IgG concentrations assessed by enzyme-linked immunosorbent assay (ELISA) in sera from blood samples collected on Days 0 (baseline), 14, 28 and 84 for those receiving a single dose of vaccine. For those receiving a second dose of vaccine, immunogenicity assessments were also conducted on Days 98 and 112. Immunogenicity was evaluated using the following metrics: geometric mean concentrations (GMCs), geometric mean fold increase (GMFIs) and seroresponse status. Seroresponse variables are normally defined in terms of exceeding a threshold.</description>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="11"/>
                <count group_id="O11" value="11"/>
                <count group_id="O12" value="12"/>
                <count group_id="O13" value="11"/>
                <count group_id="O14" value="10"/>
                <count group_id="O15" value="11"/>
                <count group_id="O16" value="12"/>
                <count group_id="O17" value="21"/>
                <count group_id="O18" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="18.7" upper_limit="41.7"/>
                    <measurement group_id="O2" value="20.7" lower_limit="11.3" upper_limit="37.9"/>
                    <measurement group_id="O3" value="16.0" lower_limit="9.4" upper_limit="27.3"/>
                    <measurement group_id="O4" value="25.4" lower_limit="14.9" upper_limit="43.4"/>
                    <measurement group_id="O5" value="20.9" lower_limit="12.0" upper_limit="36.5"/>
                    <measurement group_id="O6" value="32.3" lower_limit="19.2" upper_limit="54.5"/>
                    <measurement group_id="O7" value="17.0" lower_limit="11.7" upper_limit="24.8"/>
                    <measurement group_id="O8" value="18.5">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.36</measurement>
                    <measurement group_id="O9" value="20.9">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.17</measurement>
                    <measurement group_id="O10" value="12.1" lower_limit="6.81" upper_limit="21.48"/>
                    <measurement group_id="O11" value="13.2" lower_limit="6.68" upper_limit="26.06"/>
                    <measurement group_id="O12" value="13.1" lower_limit="7.49" upper_limit="22.91"/>
                    <measurement group_id="O13" value="9.0" lower_limit="4.33" upper_limit="18.74"/>
                    <measurement group_id="O14" value="10.4" lower_limit="6.66" upper_limit="16.17"/>
                    <measurement group_id="O15" value="16.8" lower_limit="8.19" upper_limit="34.23"/>
                    <measurement group_id="O16" value="17.7" lower_limit="11.14" upper_limit="28.02"/>
                    <measurement group_id="O17" value="16.0">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.71</measurement>
                    <measurement group_id="O18" value="22.3">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.41</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="29.4" upper_limit="77.0"/>
                    <measurement group_id="O2" value="157" lower_limit="110.9" upper_limit="220.9"/>
                    <measurement group_id="O3" value="356" lower_limit="173.8" upper_limit="731.1"/>
                    <measurement group_id="O4" value="261" lower_limit="108.9" upper_limit="625.4"/>
                    <measurement group_id="O5" value="51.1" lower_limit="27.9" upper_limit="93.7"/>
                    <measurement group_id="O6" value="116" lower_limit="64.4" upper_limit="207.4"/>
                    <measurement group_id="O7" value="213" lower_limit="141.2" upper_limit="320.3"/>
                    <measurement group_id="O8" value="20.9">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.46</measurement>
                    <measurement group_id="O9" value="20.5">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.27</measurement>
                    <measurement group_id="O10" value="35.7" lower_limit="14.11" upper_limit="90.40"/>
                    <measurement group_id="O11" value="133" lower_limit="63.16" upper_limit="278.5"/>
                    <measurement group_id="O12" value="91.7" lower_limit="37.72" upper_limit="223.0"/>
                    <measurement group_id="O13" value="67.2" lower_limit="27.82" upper_limit="162.4"/>
                    <measurement group_id="O14" value="29.0" lower_limit="14.16" upper_limit="59.39"/>
                    <measurement group_id="O15" value="60.2" lower_limit="22.53" upper_limit="161.1"/>
                    <measurement group_id="O16" value="108" lower_limit="65.39" upper_limit="179.1"/>
                    <measurement group_id="O17" value="15.8">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.71</measurement>
                    <measurement group_id="O18" value="21.5">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.53</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="30.9" upper_limit="86.4"/>
                    <measurement group_id="O2" value="185" lower_limit="141.6" upper_limit="242.3"/>
                    <measurement group_id="O3" value="338" lower_limit="172.8" upper_limit="659.4"/>
                    <measurement group_id="O4" value="232" lower_limit="92.0" upper_limit="586.9"/>
                    <measurement group_id="O5" value="50.2" lower_limit="28.4" upper_limit="88.8"/>
                    <measurement group_id="O6" value="129" lower_limit="77.9" upper_limit="213.7"/>
                    <measurement group_id="O7" value="223" lower_limit="145.2" upper_limit="342.8"/>
                    <measurement group_id="O8" value="19.4">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.43</measurement>
                    <measurement group_id="O9" value="19.5">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.32</measurement>
                    <measurement group_id="O10" value="39.8" lower_limit="15.53" upper_limit="101.8"/>
                    <measurement group_id="O11" value="166" lower_limit="78.57" upper_limit="352.6"/>
                    <measurement group_id="O12" value="103" lower_limit="43.69" upper_limit="244.0"/>
                    <measurement group_id="O13" value="81.7" lower_limit="34.20" upper_limit="195.1"/>
                    <measurement group_id="O14" value="31.2" lower_limit="15.13" upper_limit="64.34"/>
                    <measurement group_id="O15" value="68.1" lower_limit="27.19" upper_limit="170.5"/>
                    <measurement group_id="O16" value="108" lower_limit="61.93" upper_limit="187.1"/>
                    <measurement group_id="O17" value="14.8">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.91</measurement>
                    <measurement group_id="O18" value="20.7">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.54</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="34.5" upper_limit="96.9"/>
                    <measurement group_id="O2" value="159" lower_limit="119.5" upper_limit="212.2"/>
                    <measurement group_id="O3" value="313" lower_limit="176.9" upper_limit="553.5"/>
                    <measurement group_id="O4" value="223" lower_limit="133.6" upper_limit="372.5"/>
                    <measurement group_id="O5" value="46.8" lower_limit="26.4" upper_limit="82.8"/>
                    <measurement group_id="O6" value="111" lower_limit="70.5" upper_limit="176.1"/>
                    <measurement group_id="O7" value="167" lower_limit="96.9" upper_limit="289.2"/>
                    <measurement group_id="O8" value="18.8">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.46</measurement>
                    <measurement group_id="O9" value="19.6">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=2.13</measurement>
                    <measurement group_id="O10" value="39.6" lower_limit="16.93" upper_limit="92.81"/>
                    <measurement group_id="O11" value="128" lower_limit="61.02" upper_limit="267.1"/>
                    <measurement group_id="O12" value="85.0" lower_limit="35.91" upper_limit="201.5"/>
                    <measurement group_id="O13" value="68.6" lower_limit="29.02" upper_limit="162.0"/>
                    <measurement group_id="O14" value="29.4" lower_limit="14.73" upper_limit="58.66"/>
                    <measurement group_id="O15" value="59.2" lower_limit="25.66" upper_limit="136.6"/>
                    <measurement group_id="O16" value="82.5" lower_limit="45.39" upper_limit="149.8"/>
                    <measurement group_id="O17" value="14.7">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.71</measurement>
                    <measurement group_id="O18" value="24.6">95% confidence Intervals not available for this group due to insufficient number of participants with data. Standard deviations were calculated. SD=3.95</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 98</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O2" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O3" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O4" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O5" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O6" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O7" value="203">95% confidence Intervals not available for this group at Day 98 due to insufficient number of participants with data. Standard deviations were calculated. SD=2.2</measurement>
                    <measurement group_id="O8" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O9" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O10" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O11" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O12" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O13" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O14" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O15" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O16" value="93.3">95% confidence Intervals not available for this group at Day 98 due to insufficient number of participants with data. Standard deviations were calculated. SD=2.48</measurement>
                    <measurement group_id="O17" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O18" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O2" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O3" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O4" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O5" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O6" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O7" value="116">95% confidence Intervals not available for this group at Day 112 due to insufficient number of participants with data. Standard deviations were calculated. SD=6.27</measurement>
                    <measurement group_id="O8" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O9" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O10" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O11" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O12" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O13" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O14" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O15" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O16" value="57.6">95% confidence Intervals not available for this group at Day 112 due to insufficient number of participants with data. Standard deviations were calculated. SD=6.09</measurement>
                    <measurement group_id="O17" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                    <measurement group_id="O18" value="NA">Arm did not receive booster and were not evaluated at Days 98 and 112.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Monovalent rAT 10µg Dose</title>
        </group>
        <group group_id="E2">
          <title>Monovalent rAT 25µg Dose</title>
        </group>
        <group group_id="E3">
          <title>Monovalent rAT 50µg Dose</title>
        </group>
        <group group_id="E4">
          <title>Monovalent rAT 100µg Dose</title>
        </group>
        <group group_id="E5">
          <title>Monovalent rLukS 10µg Dose</title>
        </group>
        <group group_id="E6">
          <title>Monovalent rLukS 25µg Dose</title>
        </group>
        <group group_id="E7">
          <title>Monovalent rLukS 50µg Dose</title>
        </group>
        <group group_id="E8">
          <title>Monovalent rLukS 100µg Dose</title>
        </group>
        <group group_id="E9">
          <title>Bivalent rAT/rLukS 10µg Dose</title>
        </group>
        <group group_id="E10">
          <title>Bivalent rAT/rLukS 25µg Dose</title>
        </group>
        <group group_id="E11">
          <title>Bivalent rAT/rLukS 50µg Dose</title>
        </group>
        <group group_id="E12">
          <title>Alum Placebo</title>
        </group>
        <group group_id="E13">
          <title>Normal Saline Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Astrocytoma Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Haemoglobin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood LDH increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>WBC count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Numbers in each of the dose arms were small</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Tribble, MD, DrPH</name_or_title>
      <organization>Uniformed Services University of the Health Sciences</organization>
      <phone>301-816-8404</phone>
      <email>dtribble@idcrp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

